Breaking News Instant updates and real-time market news.

CLVS

Clovis

$14.75

-0.21 (-1.40%)

10:40
12/02/19
12/02
10:40
12/02/19
10:40

Dealreporter questions if Clovis 'could become a tempting target'

In a morning flash report sent prior to the open, Dealreporter said Clovis Oncology's strong Q3 earnings and subsequent advance in the stock lead the publication "to wonder whether the company could become a tempting target." Dealreporter said it "wonders if large pharma may take another look" at Clovis, but added that any large pharma buyer "would have to be very confident in its ability to compete from behind, with two other large drugmakers holding a sizable lead in the PARP class," according to contacts.

CLVS Clovis
$14.75

-0.21 (-1.40%)

10/31/19
PIPR
10/31/19
NO CHANGE
Target $4
PIPR
Neutral
Clovis price target lowered to $4 from $11 at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro lowered his price target for Clovis Oncology to $4 from $11 saying data for PARP plus PD-(L)1 continues to suggest little to no benefit over PARP monotherapy for BRCA+ patients. The analyst reiterates a Neutral rating on Clovis shares.
11/07/19
PIPR
11/07/19
NO CHANGE
PIPR
Clovis' 'solid' quarter doesn't alleviate concerns, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro reiterated a Neutral rating on Clovis Oncology, but raised his price target on shares to $4.50 from $4.00 following the company's "solid" Q3 results, which showed better-than-expected revenue from Rubraca and slowing cash burn. However, the analyst noted that Clovis' current cash is sufficient only into the second half of 2021, which is close to the time ~$100M in convertible debt comes due, and a year before the "R+N arm of ATHENA is projected to readout." Given his "concerns around ATHENA, the competitive landscape, and cash/debt," Catanzaro reiterated a Neutral rating.
11/19/19
EVER
11/19/19
DOWNGRADE
Target $8
EVER
In Line
Clovis downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst Joshua Schimmer downgraded Clovis to In Line from Outperform with an $8 price target.
11/19/19
EVER
11/19/19
DOWNGRADE
Target $8
EVER
In Line
Clovis downgraded to In Line on valuation, limited prospects at Evercore ISI
As previously reported, Evercore ISI analyst Joshua Schimmer downgraded Clovis to In Line from Outperform with a price target of $8, down from $12. The analyst said cites valuation has shot up after earnings and fundamentals challenges from a crowded PARP market limit prospects for meaningful share upside.

TODAY'S FREE FLY STORIES

BIIB

Biogen

$293.92

1.71 (0.59%)

07:32
12/13/19
12/13
07:32
12/13/19
07:32
Hot Stocks
Biogen: Primary endpoint not statistically significant in Phase 2 PASSPORT study »

Biogen announced topline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$305.76

2.01 (0.66%)

07:32
12/13/19
12/13
07:32
12/13/19
07:32
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CG

Carlyle Group

$29.83

-0.36 (-1.19%)

07:31
12/13/19
12/13
07:31
12/13/19
07:31
Hot Stocks
Funds advised by Apax Partners to acquire Coalfire from Carlyle Group, Chertoff »

Funds advised by Apax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ADBE

Adobe

$305.76

2.01 (0.66%)

07:30
12/13/19
12/13
07:30
12/13/19
07:30
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SAFM

Sanderson Farms

$166.66

2.5 (1.52%)

07:30
12/13/19
12/13
07:30
12/13/19
07:30
Initiation
Sanderson Farms initiated  »

Sanderson Farms initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

ORCL

Oracle

$56.47

0.16 (0.28%)

07:30
12/13/19
12/13
07:30
12/13/19
07:30
Recommendations
Oracle analyst commentary  »

Oracle shares to come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$327.39

7.53 (2.35%)

07:28
12/13/19
12/13
07:28
12/13/19
07:28
Recommendations
Broadcom analyst commentary  »

Broadcom price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCLH

Norwegian Cruise Line

$56.12

0.72 (1.30%)

07:27
12/13/19
12/13
07:27
12/13/19
07:27
Recommendations
Norwegian Cruise Line analyst commentary  »

Norwegian Cruise Line…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$305.76

2.01 (0.66%)

07:26
12/13/19
12/13
07:26
12/13/19
07:26
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ADBE

Adobe

$305.76

2.01 (0.66%)

07:25
12/13/19
12/13
07:25
12/13/19
07:25
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

DCP

DCP Midstream

$23.70

-0.56 (-2.31%)

07:25
12/13/19
12/13
07:25
12/13/19
07:25
Initiation
DCP Midstream initiated  »

DCP Midstream initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jan

07:25
12/13/19
12/13
07:25
12/13/19
07:25
Conference/Events
UBS analyst manley to hold an analyst/industry conference call »

Analyst Manley discusses…

TDOC

Teladoc

$77.06

-0.36 (-0.46%)

07:24
12/13/19
12/13
07:24
12/13/19
07:24
Initiation
Teladoc initiated  »

Teladoc initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$31.60

0.78 (2.53%)

07:22
12/13/19
12/13
07:22
12/13/19
07:22
Downgrade
Credit Suisse downgrades Aimmune with peanut allergy approval widely expected »

Credit Suisse analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$162.94

-4.5 (-2.69%)

07:22
12/13/19
12/13
07:22
12/13/19
07:22
Downgrade
Nordson rating change  »

Nordson downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

Bluebird Bio

$84.00

-2.97 (-3.42%)

07:20
12/13/19
12/13
07:20
12/13/19
07:20
Upgrade
Bluebird Bio rating change  »

Bluebird Bio upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

07:19
12/13/19
12/13
07:19
12/13/19
07:19
Upgrade
Bristol-Myers rating change  »

Bristol-Myers upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNS

Bank of Nova Scotia

$56.73

0.145 (0.26%)

07:19
12/13/19
12/13
07:19
12/13/19
07:19
Downgrade
Bank of Nova Scotia rating change  »

Bank of Nova Scotia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

SKX

Skechers

$41.65

0.89 (2.18%)

07:18
12/13/19
12/13
07:18
12/13/19
07:18
Upgrade
Skechers rating change  »

Skechers upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETSY

Etsy

$41.97

0.95 (2.32%)

07:17
12/13/19
12/13
07:17
12/13/19
07:17
Initiation
Etsy initiated  »

Etsy initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

07:16
12/13/19
12/13
07:16
12/13/19
07:16
Recommendations
Sarepta price target raised to $260 from $160 at H.C. Wainwright »

H.C. Wainwright analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$119.76

0.72 (0.60%)

07:15
12/13/19
12/13
07:15
12/13/19
07:15
Periodicals
Bonobos founder Andy Dunn leaving Walmart in 2020, CNBC reports »

Andy Dunn, the founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$179.27

-0.33 (-0.18%)

, MRTX

Mirati Therapeutics

$106.24

0.39 (0.37%)

07:14
12/13/19
12/13
07:14
12/13/19
07:14
Hot Stocks
BeiGene announces clinical data on tislelizumab in combination with sitravatinib »

BeiGene (BGNE) and Mirati…

BGNE

BeiGene

$179.27

-0.33 (-0.18%)

MRTX

Mirati Therapeutics

$106.24

0.39 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ADBE

Adobe

$305.76

2.01 (0.66%)

07:13
12/13/19
12/13
07:13
12/13/19
07:13
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

MPLX

MPLX

$25.26

-0.05 (-0.20%)

07:12
12/13/19
12/13
07:12
12/13/19
07:12
Initiation
MPLX initiated  »

MPLX initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.